277 related articles for article (PubMed ID: 33215235)
1. Association between lipid-lowering agents and severe hyponatremia: a population-based case-control study.
Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
Eur J Clin Pharmacol; 2021 May; 77(5):747-755. PubMed ID: 33215235
[TBL] [Abstract][Full Text] [Related]
2. Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study.
Falhammar H; Skov J; Calissendorff J; Lindh JD; Mannheimer B
Endocrine; 2020 Mar; 67(3):579-586. PubMed ID: 31875925
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
[TBL] [Abstract][Full Text] [Related]
4. Tramadol- and codeine-induced severe hyponatremia: A Swedish population-based case-control study.
Falhammar H; Calissendorff J; Skov J; Nathanson D; Lindh JD; Mannheimer B
Eur J Intern Med; 2019 Nov; 69():20-24. PubMed ID: 31416660
[TBL] [Abstract][Full Text] [Related]
5. Statin intolerance: diagnosis and remedies.
Pirillo A; Catapano AL
Curr Cardiol Rep; 2015 May; 17(5):27. PubMed ID: 25894795
[TBL] [Abstract][Full Text] [Related]
6. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
7. Reduced risk for hospitalization due to hyponatraemia in lithium treated patients: A Swedish population-based case-control study.
Falhammar H; Skov J; Calissendorff J; Lindh JD; Mannheimer B
J Psychopharmacol; 2021 Feb; 35(2):184-189. PubMed ID: 32684112
[TBL] [Abstract][Full Text] [Related]
8. Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population-Based Case-Control Study.
Falhammar H; Skov J; Calissendorff J; Nathanson D; Lindh JD; Mannheimer B
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3696-705. PubMed ID: 32285124
[TBL] [Abstract][Full Text] [Related]
9. Use of Lipid-Lowering Drugs and the Risk of Cataract: A Population-Based Nested Case-Control Study.
Bezin J; Mansiaux Y; Noize P; Salvo F; Bégaud B; Pariente A
Clin Pharmacol Ther; 2019 Feb; 105(2):458-465. PubMed ID: 29992538
[TBL] [Abstract][Full Text] [Related]
10. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
[TBL] [Abstract][Full Text] [Related]
11. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotics and severe hyponatremia: A Swedish population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Feb; 60():71-77. PubMed ID: 30514607
[TBL] [Abstract][Full Text] [Related]
13. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.
Wallach-Kildemoes H; Hansen EH
Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068
[TBL] [Abstract][Full Text] [Related]
14. Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.
Despas F; Rousseau V; Lafaurie M; De Canecaude C; Durrieu G; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2019 Dec; 33(6):695-702. PubMed ID: 31251421
[TBL] [Abstract][Full Text] [Related]
15. Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Farmand S; Skov J; Nathanson D; Mannheimer B
Seizure; 2018 Jul; 59():28-33. PubMed ID: 29730273
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany.
Jacob L; Greiner RA; Luedde M; Kostev K
J Cardiovasc Pharmacol; 2021 Dec; 78(6):885-890. PubMed ID: 34654787
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering drug prescriptions in a group of Colombian patients.
Gaviria-Mendoza A; Machado-Duque ME; Machado-Alba JE
Biomedica; 2019 Dec; 39(4):759-768. PubMed ID: 31860186
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents.
Tatley M; Savage R
Drug Saf; 2007; 30(3):195-201. PubMed ID: 17343428
[TBL] [Abstract][Full Text] [Related]
19. Lipid lowering for secondary prevention of cardiovascular disease in older adults.
Thomas JE; Tershakovec AM; Jones-Burton C; Sayeed RA; Foody JM
Drugs Aging; 2010 Dec; 27(12):959-72. PubMed ID: 21087066
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Collins PD; Sattar N
Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
